Beta

Prf technologies ltd.PRFX.US Overview

US StockHealthcare
(No presentation for PRFX)
OverviewAI AnalysisFinancialsFinancial ForecastStock SentimentalInstitutionsTradingView Chart

Ticker

Value

empty

There is no following symbol in this watchlist.

PRFX AI Insights

PRFX Overall Performance

PRFX AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

PRFX Recent Performance

-10.92%

Prf technologies ltd.

-1.10%

Avg of Sector

-0.49%

S&P500

PRFX PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

Check PRFX's Trend

PRFX Key Information

PRFX Valuation Metrics

PRFX Profile

PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.

Price of PRFX

PRFX FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

PRFX Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-54.13
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
113.27
PB Ratio
0.23
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-54.13
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
113.27
PB Ratio
0.23
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is PRFX's latest earnings report released?

    The most recent financial report for Prf technologies ltd. (PRFX) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating PRFX's short-term business performance and financial health. For the latest updates on PRFX's earnings releases, visit this page regularly.

  • How much cash does PRFX have?

    At the end of the period, Prf technologies ltd. (PRFX) held Total Cash and Cash Equivalents of 3.15M, accounting for 0.26 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.